10,214 Shares in LeMaitre Vascular, Inc. $LMAT Bought by American Century Companies Inc.

Key Points

• American Century Companies Inc. has acquired over 10,000 shares of LeMaitre Vascular, Inc. during the first quarter, valued at approximately $857,000.
• LeMaitre Vascular reported earnings of $0.60 per share for the last quarter, exceeding analysts' expectations and demonstrating a 15% year-over-year revenue growth.
• The company declared a quarterly dividend of $0.20 per share, resulting in an annualized yield of 0.8% with a payout ratio of 38.83%.

American Century Companies Inc. purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,214 shares of the medical instruments supplier's stock, valued at approximately $857,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the first quarter worth about $26,000. NBC Securities Inc. purchased a new stake in LeMaitre Vascular during the 1st quarter worth approximately $36,000. US Bancorp DE raised its position in shares of LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 368 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after buying an additional 284 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new stake in shares of LeMaitre Vascular during the first quarter worth approximately $232,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent analyst reports. Cantor Fitzgerald raised their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $97.60.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $2.98 during trading hours on Wednesday, hitting $92.64. The stock had a trading volume of 175,024 shares, compared to its average volume of 171,059. The stock's fifty day simple moving average is $89.33 and its 200 day simple moving average is $86.19. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 44.97, a PEG ratio of 2.46 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's payout ratio is 38.83%.

Insider Activity at LeMaitre Vascular

In related news, Director John A. Roush sold 6,561 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the sale, the director owned 2,916 shares of the company's stock, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 120,815 shares of company stock valued at $11,280,206. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.